Skip to content
Peptigraph home

How 5-Amino-1MQ Works: Mechanism and Pharmacology

How 5-Amino-1MQ works: its target and mechanism as the sources state them, how long it acts, and what is still unknown.

Medical review pendingNNMT inhibitor (not a peptide)Updated
Class
NNMT inhibitor (not a peptide)
FDA status
Not approved
research chemical
Routes studied
None stated
PubMed search, 11 Oct 2026
Half-life
[pending]
by route, with source

How long it acts

No published half-life found for 5-Amino-1MQ (PubMed search, 11 Oct 2026)

The enzyme it is designed to block

The target is nicotinamide N-methyltransferase (NNMT), an enzyme in the cell fluid that adds a methyl group to nicotinamide and to other substances foreign to the body.[4]

In enzyme tests, quinolinium compounds, the chemical family 5-amino-1MQ belongs to, blocked NNMT at about 1 micromolar, a test-tube measure of potency.[4]

Computer docking placed the quinolinium compounds in the enzyme pocket that normally holds nicotinamide, and the docking scores tracked the measured potency.[4]

What blocking it did in animals and cells

In obese mice, 5-amino-1MQ with a low-fat diet was linked to marked loss of body fat and weight, an animal result, and the paper does not describe a mechanism in people.[5]

In cultured human cervical cancer cells, 5MQ lowered the levels of the proteins phospho-Akt and SIRT1, which are cell measurements.[6]

In cultured osteosarcoma and Merkel cell carcinoma cells, NNMT inhibitors raised reactive oxygen species and activated cell-death pathways, cell data only.[7]

What is not known

The safety-focused PubMed query run on 2026-10-11 for ("5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) found 0 results.

Calculated from query ("5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]); date 2026-10-11; result count 0. Formula: count reported by the search record in the evidence file

The authors of the enzyme study describe the compounds as a design guide for future drug-like inhibitors, so none of the cached work describes a finished medicine.[4]

Common questions

How long does 5-Amino-1MQ act in the body?

We found no published half-life for 5-Amino-1MQ (PubMed search, 11 Oct 2026), so how long it acts is unknown.

How does 5-amino-1MQ work?

It is a small molecule designed to inhibit the enzyme NNMT.[6]

Does 5-amino-1MQ work in people?

The weight-loss finding comes from obese mice. No study of people is among the sources cached for this page.[5]

More on 5-Amino-1MQ

Sources

  1. 1PubMed search: "5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab] (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  2. 2PubMed search: nicotinamide N-methyltransferase[tiab] AND (quinolinium[tiab] OR 5-amino-1MQ[tiab] OR "5-amino-1-methylquinolinium"[tiab] OR 5MQ[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  3. 3PubMed search: ("5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (0 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  4. 4Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase.Journal of medicinal chemistry · 2017PMID 28548833Accessed 2 Oct 2026
  5. 5Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.Scientific reports · 2022PMID 35013352Accessed 2 Oct 2026
  6. 6Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2021PMID 33645410Accessed 2 Oct 2026
  7. 7Small Molecule Inhibitors of Nicotinamide N-Methyltransferase Enzyme for the Treatment of Osteosarcoma and Merkel Cell Carcinoma: Potential for the Development of a Targeted Therapeutic Strategy.Biomolecules · 2025PMID 41301471Accessed 2 Oct 2026

Found an error? Report a correction.